Evidence map›Paper›PMID 25670082›Full record

ArticleCancer cell2015

Recurrent DGCR8, DROSHA, and SIX homeodomain mutations in favorable histology Wilms tumors.

Amy L Walz, Ariadne Ooms, Samantha Gadd, Daniela S Gerhard, Malcolm A Smith, Jaime M Guidry Auvil, Jamie M Guidry Auvil, Daoud Meerzaman, Qing-Rong Chen, Chih Hao Hsu and 21 more

Erratum issuedOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 166 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
166citing papers in PubMed, 4 pooled it
13.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

166 citing papers in PubMed, 4 syntheses or guidelines pooled it, 286 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Germline Pathogenic DROSHA Variants Are Linked to Pineoblastoma and Wilms Tumor Predisposition.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Article

106 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

  • Erratum issued
    Guidry Auvil, Jamie M [corrected to Guidry Auvil, Jaime M]
5 · Who and what money

Authors and funding

31 authors at 11 institutions in 3 countries.

Amy L WalzDivision of Hematology-Oncology and Transplantation, Ann and Robert H. Lurie Children's Hospital of Chicago, Northwestern University's Feinberg School of Medicine, Chicago, IL 60611, USA.
Ariadne OomsDepartment of Pathology, Josephine Nefkens Institute, Erasmus Medical Center, Rotterdam CA 3000, the Netherlands.
Samantha GaddDepartment of Pathology and Laboratory Medicine, Lurie Children's Hospital, Northwestern University's Feinberg School of Medicine and Robert H. Lurie Cancer Center, Chicago, IL 60611, USA.
Daniela S GerhardOffice of Cancer Genomics, National Cancer Institute, Bethesda, MD 20892, USA.
Malcolm A SmithCancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD 20892, USA.
Jaime M Guidry Auvil
Jamie M Guidry AuvilOffice of Cancer Genomics, National Cancer Institute, Bethesda, MD 20892, USA.
Daoud MeerzamanCenter for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, MD 20892, USA.
Qing-Rong ChenCenter for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, MD 20892, USA.
Chih Hao HsuCenter for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, MD 20892, USA.
Chunhua YanCenter for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, MD 20892, USA.
Cu NguyenCenter for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, MD 20892, USA.
Ying HuCenter for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, MD 20892, USA.
Reanne BowlbyCanada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC V5Z 4S6, Canada.
Denise BrooksCanada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC V5Z 4S6, Canada.
Yussanne MaCanada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC V5Z 4S6, Canada.
Andrew J MungallCanada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC V5Z 4S6, Canada.
Richard A MooreCanada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC V5Z 4S6, Canada.
Jacqueline ScheinCanada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC V5Z 4S6, Canada.
Marco A MarraCanada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC V5Z 4S6, Canada; Department of Medical Genetics, University of British Columbia, Vancouver, BC V6H 3N1, Canada.
Vicki HuffDepartment of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jeffrey S DomeDivision of Pediatric Hematology/Oncology, Children's National Medical Center, Washington, DC 20010, USA.
Yueh-Yun ChiDepartment of Biostatistics, University of Florida, Gainesville, FL 32610, USA.
Charles G MullighanDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Jing MaDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
David A WheelerDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA.
Oliver A HamptonDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA.
Nadereh JafariCenter for Genetic Medicine, Northwestern University, Chicago, IL 60611, USA.
Nicole RossDepartment of Pathology and Laboratory Medicine, Nationwide Children's Hospital, Ohio State University College of Medicine, Columbus, OH 43205, USA.
Julie M Gastier-FosterDepartment of Pathology and Laboratory Medicine, Nationwide Children's Hospital, Ohio State University College of Medicine, Columbus, OH 43205, USA.
Elizabeth J PerlmanDepartment of Pathology and Laboratory Medicine, Lurie Children's Hospital, Northwestern University's Feinberg School of Medicine and Robert H. Lurie Cancer Center, Chicago, IL 60611, USA. Electronic address: eperlman@luriechildrens.org.
National Cancer Institute · USCanada's Michael Smith Genome Sciences Centre · CABaylor College of Medicine · USNationwide Children's Hospital · USNorthwestern University · USRobert H. Lurie Comprehensive Cancer Center of Northwestern UniversitySt. Jude Children's Research Hospital · USChildren's National · USMeertens Institute · NLThe University of Texas MD Anderson Cancer Center · USUniversity of Florida · US

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
COG FOREIGN ACCRUALU10CA098543 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI ADAMSON, PETER C. · 2003 to 2013
$335.5M
Support for Human Specimen Banking in NCI-Supported Cancer Clinical TrialsU24CA114766 · NCI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI RAMIREZ MILAN, NILSA DEL CARMEN · 2005 to 2014
$14.5M
CLINICAL ONCOLOGY RESEARCH TRAINING PROGRAMT32CA079447 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LICHT, JONATHAN D. · 1999 to 2013
$3.1M
NWTSG Foreign AccrualU10CA042326 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI GREEN, DANIEL MICHAEL · 1985 to 2003
$2.8M
CATEGORIZATION OF WILMS TUMOR BY GENETIC EXPRESSIONU01CA088131 · NCI · LURIE CHILDREN'S HOSPITAL OF CHICAGO · PI PERLMAN, ELIZABETH J · 2001 to 2006
$1.7M
CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENCI NIH HHS T32 CA079447NCI NIH HHS U01 CA088131NCI NIH HHS U10 CA098543NCI NIH HHS U10 CA180886NCI NIH HHS U10CA42326NCI NIH HHS U10 CA98543NCI NIH HHS U10CA98543NCI NIH HHS U24 CA114766NCI NIH HHS UO1CA88131
6 · The paper itself

Abstract

We report the most common single-nucleotide substitution/deletion mutations in favorable histology Wilms tumors (FHWTs) to occur within SIX1/2 (7% of 534 tumors) and microRNA processing genes (miRNAPGs) DGCR8 and DROSHA (15% of 534 tumors). Comprehensive analysis of 77 FHWTs indicates that tumors with SIX1/2 and/or miRNAPG mutations show a pre-induction metanephric mesenchyme gene expression pattern and are significantly associated with both perilobar nephrogenic rests and 11p15 imprinting aberrations. Significantly decreased expression of mature Let-7a and the miR-200 family (responsible for mesenchymal-to-epithelial transition) in miRNAPG mutant tumors is associated with an undifferentiated blastemal histology. The combination of SIX and miRNAPG mutations in the same tumor is associated with evidence of RAS activation and a higher rate of relapse and death.

Indexed as

Gene Expression Regulation, NeoplasticHomeodomain ProteinsHumansLoss of HeterozygosityMicroRNAsMutationNeoplasm Recurrence, LocalNerve Tissue ProteinsPolymorphism, Single NucleotideRibonuclease IIIRNA-Binding ProteinsWilms TumorDGCR8 protein, humanDROSHA protein, humanHomeodomain ProteinsMicroRNAsmirnlet7 microRNA, humanNerve Tissue ProteinsRibonuclease IIIRNA-Binding ProteinsSIX1 protein, humanSIX2 protein, human

Identifiers

PMID25670082
PMCPMC4800737
OpenAlexW2046368638

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.